In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder

Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties. Methods: Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment. Results: Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities. Conclusions: Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.

Authors

Publication Details

Journal
Pharmaceuticals
Published
2026-11-18
DOI
https://doi.org/10.3390/ph19111839
Primary Topic
Cholinesterase and Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder

Faizah A. Binjubair, Haneen A. Al‐Mazroua, Hatun A. Alomar, Ahmed H.H. Bakheit et al.
3 links
Pharmaceuticals
Cholinesterase and Neurodegenerative Diseases
article

In Silico and In Vitro Studies on Selective MAO-B Inhibition and Predicted Microbiome Interactions of Novel Chalcone Derivatives: Relevance to the Gut–Brain Axis in Autism Spectrum Disorder

Faizah A. Binjubair, Haneen A. Al‐Mazroua, Hatun A. Alomar, Ahmed H.H. Bakheit, Nawaf A. Alsaif, Huda S. Al-Salem, Duaa A. Aqeel
article en

Abstract

Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties. Methods: Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment. Results: Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities. Conclusions: Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.

PharmaceuticalsVol. 19(11)
King Saud University
Good health and well-being
Cholinesterase and Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon